[{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Friendship Hospital \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Friendship Hospital \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People\u2019s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Rectal","sponsorNew":"Beijing Friendship Hospital \/ New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People\u2019s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People\u2019s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Chymotrypsin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Beijing Friendship Hospital \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Friendship Hospital \/ Beijing Friendship Hospital"}]

Find Clinical Drug Pipeline Developments & Deals by Beijing Friendship Hospital

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : Recombinant Human Chymotrypsin

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Recipient : Healthgen Biotechnology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 04, 2024

                          Lead Product(s) : NCR300

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Beijing Friendship Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Lead Product(s) : Tislelizumab

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 18, 2022

                          Lead Product(s) : Tislelizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Lead Product(s) : Capecitabine

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People’s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 03, 2021

                          Lead Product(s) : Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People’s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 05, 2020

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Recipient : CSPC Baike

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 14, 2018

                          Lead Product(s) : Autologous Tcm Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Newish Technology Beijing

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 01, 2016

                          Lead Product(s) : Donepezil

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Eisai | Xuanwu Hospital, Beijing

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 20, 2013

                          Lead Product(s) : Tauroursodeoxycholic Acid

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase III

                          Sponsor : Beijing Trendful Kangjian Medical Information Consulting Limited Company

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank